Tivozanib is an orally active indole-quinolinone that selectively blocks vascular endothelial growth factor receptor-1, -2, and -3 kinases at single-digit nanomolar potency, suppressing angiogenesis and driving antitumor responses.
Usually ships within 24 hours.